Drupal.behaviors.print = function(context) {window.print();window.close();}>
Quanterix's AccuPSA Test Predicts Five-Year Recurrence-Free Survival in Prostate Cancer Study
October 21, 2011
Quanterix's AccuPSA Test Predicts Five-Year Recurrence-Free Survival in Prostate Cancer Study
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Shifting Focus From Dx Development, Quanterix Aims to Launch Commercial SiMoA Instrument in 2013
February 25, 2011 / ProteoMonitor
Study Shows Quanterix's Single Molecule Array Assay Measures PSA at Previously Undetectable Levels
June 11, 2010 / ProteoMonitor
Plasmonic ELISA Offers High-Sensitivity Protein Assay Readable by the Naked Eye
November 2, 2012 / ProteoMonitor
Quanterix Study Suggests Simoa Platform Can Compete with Nucleic Acid-Based HIV Tests
October 12, 2012 / ProteoMonitor
Quanterix Building Commercial Team Ahead of Planned 2013 Launch for Simoa Platform
July 24, 2012 / BioArray News